公开(公告)号：US20230278985A1

公开(公告)日：2023-09-07

申请号：US18019747

申请日：2021-08-02

申请人： INXMED (NANJING) CO., LTD.

发明人： Zaiqi WANG ,  Jing GAO ,  Yingxia SANG

IPC分类号： C07D401/14

CPC分类号： C07D401/14 ,  C07B2200/13

摘要： Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.

公开(公告)号：US20230079055A1

公开(公告)日：2023-03-16

申请号：US17797867

申请日：2021-01-29

申请人： INXMED (NANJING) CO., LTD.

发明人： Zaiqi WANG ,  Jiangwei ZHANG

IPC分类号： A61K31/506 ,  A61K31/704 ,  A61K9/127 ,  A61K31/337 ,  A61P35/00

摘要： The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.

公开(公告)号：US20210230171A1

公开(公告)日：2021-07-29

申请号：US15734986

申请日：2019-06-03

申请人： InxMed (Nanjing) Co., Ltd.

发明人： Zaiqi WANG ,  Lihu YANG

IPC分类号： C07D487/14 ,  A61K9/00

摘要： The present invention relates to a selective A2A receptor antagonist, and in particular to a selective A2A receptor antagonist of Formula (I), a pharmaceutical composition comprising the antagonist, use of the antagonist in manufacturing a medicament and in treatment of a disease: wherein the groups in Formula (I) are defined as in the specification.

公开(公告)号：US20230364088A1

公开(公告)日：2023-11-16

申请号：US18350303

申请日：2023-07-11

申请人： INXMED (NANJING) CO., LTD.

发明人： Zaiqi WANG ,  Jiangwei ZHANG ,  Jun JIANG

IPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P19/04 ,  A61P35/00 ,  A61K31/4439 ,  A61P17/00 ,  A61P1/00

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P19/04 ,  A61P35/00 ,  A61K31/4439 ,  A61P17/00 ,  A61P1/00

摘要： A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230145356A1

公开(公告)日：2023-05-11

申请号：US17777769

申请日：2020-11-17

申请人： INXMED (NANJING) CO., LTD.

发明人： Zaiqi WANG ,  Jiangwei ZHANG ,  Jun JIANG

IPC分类号： A61K31/506 ,  A61K31/4439 ,  A61K31/5377 ,  A61P35/00 ,  A61K45/06 ,  A61P19/04 ,  A61P1/00 ,  A61P17/00

CPC分类号： A61K31/506 ,  A61K31/4439 ,  A61K31/5377 ,  A61P35/00 ,  A61K45/06 ,  A61P19/04 ,  A61P1/00 ,  A61P17/00

摘要： A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230000867A1

公开(公告)日：2023-01-05

申请号：US17780397

申请日：2020-11-27

申请人： INXMED (NANJING) CO., LTD.

发明人： Zaiqi WANG ,  Jiangwei ZHANG ,  Jun JIANG ,  Baoyuan ZHANG

IPC分类号： A61K31/513 ,  A61P35/00 ,  A61K31/519

摘要： The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.